Compare Johnson & Johnson (JNJ) vs MINISO Group Holding Ltd (MNSO) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

MNSO trades at $12.79, up 0.31% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.591 versus $0.238 expected, and announced a HK$2 billion share repurchase program on June 29, 2026 (PRNewsWire). Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 13.02, indicating reasonable valuation.

The outlook is positive with projected revenue growth to $22.7 billion in 2026 and net profit doubling to $2.0 billion. However, risks include margin compression from rising expenses and mixed earnings history with two recent misses. Analyst consensus is 75% buy, but competitive pressures in retail remain a concern for sustained profitability.